From Wikipedia, the free encyclopedia

Propofol
Systematic (IUPAC) name
2,6-diisopropylphenol
Identifiers
CAS number	2078-54-8
ATC code	N01AX10
PubChem	4943
DrugBank	APRD01201
Chemical data
Formula	C12H18O
Mol. mass	178.271 g/mol
Pharmacokinetic data
Bioavailability	NA
Protein binding	95 to 99%
Metabolism	Hepatic glucuronidation
Half life	30 to 60 min
Excretion	Renal
Therapeutic considerations
Pregnancy cat.	B (U.S.), C (Au)
Legal status	℞-only (U.S.)
Routes	Intravenous

Propofol is a short-acting intravenous anesthetic agent used for the induction of general anesthesia in adult patients and pediatric patients older than 3 years of age; maintenance of general anesthesia in adult patients and pediatric patients older than 2 months of age; and sedation in medical contexts, such as intensive care unit (ICU) sedation for intubated, mechanically ventilated adults, and in procedures such as colonoscopy. It provides no analgesia.^[1]

Propofol is approved for the induction and maintenance of anesthesia in more than 50 countries.

It is also commonly used in veterinary medicine and many veterinary anaesthetists regard it as the induction agent of choice for small animals (dogs, cats etc) as it can be administered to effect, reducing the risk of accidental overdose.

20 ml ampoule of 1% propofol emulsion

Propofol is a water-immiscible oil and so cannot be injected per se. Initial clinical trials were in 1977, in a form solubilised in cremophor EL, but due to anaphylactic reactions it was withdrawn from the market. It was subsequently reformulated as an emulsion of a soya oil/propofol mixture in water, and re-launched in 1986 by AstraZeneca with the brand name Diprivan (shortened version of DI-isoPRopyl IV ANesthetic). The current preparation is 1% propofol, 10% soybean oil and 1.2% purified egg phospholipid (emulsifier), with 2.25% of glycerol as a tonicity adjusting agent, and sodium hydroxide to adjust the pH. Diprivan contains EDTA as an antimicrobial agent. Newer generic formulations contain sodium metabisulfite or benzyl alcohol. Propofol emulsion appears as a highly opaque white fluid due to the scattering of light from the tiny (~150 nm) oil droplets that it contains.

A water soluble form of the drug, propofol phosphate, has recently been developed and tested in animals with positive results, being rapidly broken down once in the body to form propofol. This new formulation might well have superior properties for use in humans such as being more readily injectable and perhaps without the pain at injection site that often occurs with the traditional form of the drug.^[2] Fospropofol disodium is rapidly converted into propofol by the enzyme alkaline phosphatase, and is now being developed for human use under the brand name Aquavan.[1]

Propofol is highly protein bound in vivo and is metabolised by conjugation in the liver. Its rate of clearance exceeds hepatic blood flow, suggesting an extrahepatic site of elimination as well. Its mechanism of action is uncertain, but it is postulated that its primary effect may be potentiation of the GABA-A receptor, possibly by slowing the channel closing time. Recent research has also suggested the endocannabinoid system may contribute significantly to Propofol's anesthetic action and to its unique properties.^[3]

The elimination half-life of propofol has been estimated to be between 2–24 hours. However, its duration of clinical effect is much shorter because propofol is rapidly distributed into peripheral tissues, and its effects therefore wear off considerably within even a half hour of injection. This, together with its rapid effect (within minutes of injection) and the moderate amnesia it induces makes it an ideal drug for IV sedation.

Aside from the hypotension (mainly through vasodilatation) and transient apnea following induction doses, one of propofol's most frequent side effects is pain on injection, especially in smaller veins. This pain can be mitigated by pretreatment with lidocaine.^[4] Patients tend to show great variability in their response to propofol, at times showing profound sedation with small doses. A more serious but rare side effect is dystonia. Mild myoclonic movements are not uncommon, as with other intravenous hypnotic agents. Propofol appears to be safe for use in porphyria, and has not been known to trigger malignant hyperpyrexia.

Another recently described rare, but serious, side effect is propofol infusion syndrome. This potentially lethal metabolic derangement has been reported in critically-ill patients after a prolonged infusion of high-dose propofol in combination with catecholamines and/or corticosteroids.^[5]

Abuse of propofol as a recreational drug has been reported, usually by medical staff such as anaesthesiologists who have access to the drug. Despite a lack of analgesic properties, propofol's sedative action presumably produces euphoric effects. The steep dose response curve of the drug makes such abuse very dangerous without proper monitoring, and several deaths have been recorded.^[6][7]

1. ^ Miner JR, Burton JH. Clinical practice advisory: Emergency department procedural sedation with propofol. Annals of Emergency Medicine. 2007 Aug;50(2):182-7, 187.e1. Epub 2007 Feb 23.
2. ^ Banaszczyk MG, Carlo AT, Millan V, Lindsey A, Moss R, Carlo DJ, Hendler SS. Propofol phosphate, a water-soluble propofol prodrug: in vivo evaluation. Anesthesia and Analgesia. 2002 Nov;95(5):1285-92
3. ^ Fowler, CJ. "Possible involvement of the endocannabinoid system in the actions of three clinically used drugs." Trends Pharmacol. Sci. 2004 Feb;25(2):59-61.
4. ^ Propofol Drug Information,Professional. drugs.com. Retrieved on 2007-01-02.
5. ^ Vasile B, Rasulo F, Candiani A, Latronico N (2003). "The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome". Intensive care medicine 29 (9): 1417-25. doi:10.1007/s00134-003-1905-x. PMID 12904852. 
6. ^ Iwersen-Bergmann S, Rösner P, Kühnau HC, Junge M, Schmoldt A. Death after excessive propofol abuse. International Journal of Legal Medicine. 2001;114(4-5):248-51.
7. ^ Kranioti EF, Mavroforou A, Mylonakis P, Michalodimitrakis M. Lethal self administration of propofol (Diprivan). A case report and review of the literature. Forensic Science International. 2007 Mar 22;167(1):56-8. Epub 2006 Jan 23.

• Diprivan web site run by AstraZeneca
• Detailed pharmaceutical information